Press Releases

Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd

“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.

The “one and done” era for orphan drugs: Evaluate predicts 12% growth, driven by new technologies, but benefits go to big pharma

Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019

Evaluate Ltd. appoints Deborah Kobewka as Chief Executive Officer

Biopharma in 2018: A year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong

Vantage releases annual analysis of Pharma, Biotech and Medtech performance

Uncertainty for pharma and biotech in 2019 as sector stumbles at the end of 2018

Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019

Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players

Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference

Small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers

Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018

Worldwide Prescription Drug Sales Accelerate To $1.2 Trillion By 2024, As Unmet Need Drives Annual Compound Growth To Over 6%

Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.

Worldwide Orphan Drug Sales Are Forecast To Grow At A Cagr Of 11.3% From 2018 To 2024, Double The Rate Forecast For The Non-Orphan Drug Market

Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.

Fast Pace Of Drug And Device Approvals In 2017 Signals Wider Sector Health For Biopharma But Medtech Companies Struggle

EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.